Browsing: Setbacks

The U.S. FDA granted approval for Sarclisa, Sanofi’s wearable injector blood cancer drug, offering multiple myeloma patients a convenient alternative to traditional intravenous infusions. Meanwhile, Elevar and Hengrui faced another setback as their liver cancer therapy was rejected by the FDA over recurring manufacturing deficiencies